By monitoring the CSC marker CD24 during doxorubicin treatment in MDA-MB-231 breast cancer cells, we have shown the uniform conversion of CD24− population into CD24+ cells, which we have identified as drug-resistant cells. Here, CD24 is linked to breast carcinoma.